Geode Capital Management LLC Purchases 4,731 Shares of Mural Oncology plc (NASDAQ:MURA)

Geode Capital Management LLC raised its position in Mural Oncology plc (NASDAQ:MURA) by 2.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 190,056 shares of the company’s stock after purchasing an additional 4,731 shares during the quarter. Geode Capital Management LLC owned 1.12% of Mural Oncology worth $595,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of MURA. Rhumbline Advisers bought a new position in Mural Oncology in the second quarter valued at about $34,000. Acadian Asset Management LLC bought a new position in shares of Mural Oncology during the second quarter worth about $998,000. Dimensional Fund Advisors LP bought a new position in shares of Mural Oncology during the second quarter worth about $71,000. Renaissance Technologies LLC bought a new position in shares of Mural Oncology during the second quarter worth about $729,000. Finally, Primecap Management Co. CA bought a new position in shares of Mural Oncology during the second quarter worth about $740,000. 80.21% of the stock is currently owned by institutional investors.

Mural Oncology Price Performance

NASDAQ MURA opened at $3.89 on Friday. The business has a 50 day simple moving average of $3.55 and a 200 day simple moving average of $3.39. Mural Oncology plc has a one year low of $2.87 and a one year high of $5.62. The stock has a market capitalization of $66.21 million, a P/E ratio of -0.43 and a beta of 3.83.

Insider Buying and Selling

In other Mural Oncology news, CFO Adam D. Cutler sold 7,421 shares of the firm’s stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $3.41, for a total value of $25,305.61. Following the completion of the sale, the chief financial officer now owns 71,438 shares of the company’s stock, valued at approximately $243,603.58. This trade represents a 9.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MURA. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Mural Oncology in a research report on Monday, November 11th. Raymond James began coverage on Mural Oncology in a research report on Friday, October 4th. They set a “strong-buy” rating and a $18.00 price objective for the company.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.